Matilda Bingham
Direttore/Membro del Consiglio presso Redx Oncology Ltd.
Profilo
Matilda Bingham is currently working as an Executive Director at Redx Oncology Ltd.
since 2015.
Prior to this, she worked as the Head of Research & Operations at Redx Pharma Plc.
Posizioni attive di Matilda Bingham
| Società | Posizione | Inizio |
|---|---|---|
Redx Oncology Ltd.
 Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | Direttore/Membro del Consiglio | 05/11/2015 |
Precedenti posizioni note di Matilda Bingham
| Società | Posizione | Fine |
|---|---|---|
| REDX PHARMA PLC | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| REDX PHARMA PLC | Health Technology |
| Aziende private | 1 |
|---|---|
Redx Oncology Ltd.
Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | Health Technology |
- Borsa valori
- Insiders
- Matilda Bingham
